Citations

Clear

4 citation(s) found for "Zhao, Yan".

Abstract 6307: Feasibility of a survivorship app for black prostate cancer survivors: Results from a 12-week mHealth pilot study
Kumar, Gaurav, Ghasemi, Parisa , Zhao, Yan D., Dwyer, Kathleen, Kaninjing, Ernie, Young, Mary Ellen , Sabrina, Dickey, Bolajoko, Opeyemi , Ogunsanya, M., Dwyer, Kathleen , Kumar, Gaurav , Nagykáldi, Zsolt , McIntosh, Andrew G. , Dickey, Sabrina L. , Morton, Daniel J. , Kendzor, Darla E. , Ogunsanya, Motolani E.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 6307-6307

10.1158/1538-7445.am2026-6307 Get It

Abstract Introduction: Black prostate cancer (CaP) survivors experience unique quality-of-life (QoL) and recovery challenges after treatment compared with their White counterparts. Smartphone-delivered mobile health interventions offer promising avenues for symptom tracking and lifestyle changes; but their feasibility, user engagement, and acceptability in this population remain unclear. This study assessed the feasibility, engagement, and preliminary impact of the Survivorship App for Ethnically Diverse Black Prostate Cancer Survivors (SAFE-CaPS), designed to improve self-monitoring behaviors and health outcomes. Methods: Nine Black CaP survivors (seven U.S.-born, one African-born, and one Caribbean-born) participated in a 12-week pilot study of SAFE-CaPS. The app provided daily prompts for symptoms (pain, sleep, fatigue, sexual function, anxiety, depression) and behavior tracking (physical activity, diet), brief self-management support, and physician alerts for severe symptom reports. Mental health (GAD-7 and PHQ-9) and QoL (FACT-P) were assessed at baseline and after 12 weeks. Feasibility was evaluated based on adherence rates (i.e., ≥70% of daily diary entries). Engagement and acceptability were assessed via app analytics and qualitative interviews on usability and cultural relevance. Participants were compensated up to $125 via Greenphire ClinCard. Surveys were analyzed with SPSS v29, and interviews with Atlas.ti v23. Results: Participants’ median age at diagnosis was 56 years; six had a positive family history of CaP, and four had undergone radical prostatectomy. Four participants met the feasibility threshold, and eight completed the study. Most daily entries reflected mild pain, fatigue, bowel and urinary issues, and generally good sleep. Several participants frequently reported severe sexual dysfunction, and most diary responses indicated <20 minutes of physical activity per day. Fruit/vegetable intake was low, with about half of daily responses showing 1-2 servings. At baseline, eight participants had minimal anxiety, while five had moderate depression. Overall, QoL improved from week 1 to week 12 in physical, emotional, and functional well-being, while social well-being declined over time. Interviews emphasized the app’s user-friendly design, ease of navigation, and acceptability as key strengths, with several participants highlighting its simplicity and ease of use, with recommendations to reduce repetitive items and address minor technical issues. Conclusions: SAFE-CaPS was feasible and well accepted. Sexual dysfunction, low physical activity, and moderate depression emerged as key concerns, heightening the need for integrated mental health, activity support, and stronger engagement strategies in future mHealth interventions. Citation Format: Gaurav Kumar, Parisa Ghasemi, Yan D. Zhao, Zsolt Nagykaldi, Kathleen A. Dwyer, Andrew G. McIntosh, Ernie Kaninjing, Mary E. Young, Dickey Sabrina, Daniel Morton, Opeyemi Bolajoko, Darla E. Kendzor, Motolani Ogunsanya. Feasibility of a survivorship app for black prostate cancer survivors: Results from a 12-week mHealth pilot study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6307.
Abstract 2483: Survivorship and sexual health: What we learned from Black men in community town halls
Ghasemi, Parisa , Kumar, Gaurav, Ayanambakkam, Adanma, Siston, Amy, Neil, Jordan M., Alexander, Adam, Zhao, Yan D., Dwyer, Kathleen, Young, Mary Ellen , Bolajoko, Opeyemi , Ogunsanya, M., Dwyer, Kathleen , Kumar, Gaurav , Kaninjing, Ernest , Ayanambakkam, Adanma , Nyame, Yaw A. , Neil, Jordan M. , McIntosh, Andrew G. , Nagykáldi, Zsolt , Dickey, Sabrina L. , Morton, Daniel J. , Kendzor, Darla E. , Ogunsanya, Motolani E.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2483-2483

10.1158/1538-7445.am2026-2483 Get It

Abstract Background: Prostate cancer (CaP) is among the most common cancers in U.S. men, with Black men experiencing a 1.7-fold higher incidence and nearly twice the mortality rate compared with non-Hispanic White men. While early detection has improved survival, differences remain in recovery and quality of life (QoL). Sexual dysfunction after treatment affects identity, relationships, and well-being, yet stigma, cultural norms, and limited access to patient-centered care prevent open discussion. Few initiatives address the intersection of identity, stigma, and survivorship in this population. Community town halls provide a trusted, culturally responsive space for shared learning, peer connection, and open dialogue on survivorship and sexual health. Methods: Two community-engaged CaP town halls were convened by the Multidisciplinary Health Outcomes Research and Economics (MORE) Lab at the University of Oklahoma Health Campus (OUHC) to explore survivorship issues among Black CaP survivors. The first, held virtually in June 2024, included watch parties in Georgia and Texas. The second, in November 2024, was hybrid, hosted at OUHC and via Teams with a watch party at the Willa D. Johnson Recreation Center, a community center in Oklahoma City. Panelists included oncologists, psychologists, survivors, partners, and Community Advisory Board members. Both town halls featured survivor storytelling, provider Q&A, and interactive discussion. Post-event surveys captured demographics, satisfaction, and impact. Open-discussion transcripts were analyzed using Braun and Clarke’s reflexive thematic analysis, guided by a constructivist framework. Results: A total of 124 participants attended both town halls. Survey respondents (n=17; 13.7%) provided demographic and satisfaction data; remaining insights came from all participants who engaged in open dialogue. Respondents ranged in age from 19-76 years (mean=48.7 ± 21.8). Of the 17 respondents, 93% rated the events as very good or excellent; 23.5% were CaP survivors, all identifying as Black. Five themes emerged: (1) Masculinity, stigma, and silence limit help-seeking; (2) Sexual dysfunction and identity loss cause major emotional burdens; (3) Navigation challenges highlight systemic barriers; (4) Spousal and psychological support aid coping; and (5) Survivorship empowerment. Participants valued hearing “real stories from real men,” validating their experiences. Conclusions: Community town halls are a feasible and culturally relevant strategy to engage Black CaP survivors in survivorship and sexual health discussions. By centering lived experiences and facilitating two-way communication between survivors, clinicians, and researchers, these events build trust and reduce stigma. Future work will assess changes in knowledge, engagement, and confidence in care navigation and explore scaling this community-academic model to improve survivorship QoL. Citation Format: Parisa Ghasemi, Gaurav Kumar, Ernest T. Kaninjing, Adanma Ayanambakkam, Yaw A. Nyame, Amy Siston, Jordan M. Neil, Adam C. Alexander, Andrew G. McIntosh, Yan Zhao, Zsolt Nagykaldi, Kathleen A. Dwyer, Mary Ellen Young, Sabrina Dickey, Daniel Morton, Opeyemi Bolajoko, Darla E. Kendzor, Motolani E. Ogunsanya. Survivorship and sexual health: What we learned from Black men in community town halls [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2483.
Establishing Reference Values in Healthy Participants for the Cardiac Troponin T High-Sensitivity Gen 6 Assay: REF-TSIX Global Reference Study
Daniels, Lori B. , Mueller, Christian, Giannitsis, Evangelos, Meex, Steven J. R., Buehlmann, David, Dilba, Peter, Bendig, Garnet, Cole, Mette, Body, Richard, Christenson, Robert H, deFilippi, Christopher R, Inoue, Kenji, Jaffe, A S, McCarthy, Cian P. , McCord, J., Neumann, Johannes T, Omland, T., Papendick, Cynthia , Sandoval, Yader, Twerenbold, Raphael, Peacock, W Frank, Mills, Nicholas L, investigators, the TSIX, Jacobs, Michael B., Lucksinger, Gregg, Powell, Richard, Johnson, Daniel, Coleman, Hugh, Fein, M, Surber, Joseph, Vu, Jack B., Hassman, Michael, Hernandez, John, Kirstein, Judith, Tomaszewski, Christian, Runyon, Michael S. , Gong, Jonathan , Wein, D., Andrabi, Sara , Kopin, David , Larrain, Germain, Tahirkheli, Naheem, Clemency, Brian, Abdullah, Shuaib, Hira, Ravi S. , Klausner, H A, Mahler, Simon A. , Crystal, Chad, Headden, Gary, Chaille, Peter, Cannon, Chad Aaron, Limkakeng, Alexander, Tolia, Vaishal , Knapp, Barry J., Massoomi, Mohammad, Sandoval, Yader, Ko, Emily, Luzzi, Verónica, Christenson, Robert, Carson, Jennifer Powers , Cacioppo, F , Kolev, E., Petrov, Andrey, Hazarbasanov, Dobri , Simova, lana, Magimaiseelan, Luci Suganthi, Kosch, Christine, Klein, G, Mehltretter, Kai, Sauter, Joachim, Baumann, Sybille, Moeckel, Martin, Twerenbold, Raphael, Muller-Hennessen, Matthias, Biener, Moritz , Findeisen, P., Omland, Torbjøm, Wilczek-Kosowska, Urszula, Zimmer-Satora, Ewa, Krecipro-Nizińska, Ewa, Miró, O, Díaz, Víctor Jiménez , Mueller, C, Christ, Michael, Lynch, Stephen, BODY, R. A. F., Matsuki, Shunji, Eto, Takashi, Tanaka, Takanori, Hanada, Ryuzo, Nakagami, Takuo, Nakama, T, Kadota, K., Jing, Shan, Yu, Shuwen, Zhang, Hongxuan, Zhang, Jun, Huo, Yong, Zhang, Yan, Yan, Li, Jiang, Longyuan, Chen, Weiqiang, Huang, Jianying, Zhao, Yan, Guan, Ling, Yang, Yanhua, Zhang, Qin, Qiu, Zhaohui, Body, Richard , Neumann, Franz–Josef , Müller, Christian , Mueller, Christian , Body, Rick , Eggers, Kai M. , Jaffe, Allan S. , Neumann, Johannes T , Sandoval, Yader , Tan, Jack Wei Chieh , Than, Martin , Twerenbold, Raphael , Mills, Nicholas L , Daniels, Lori B , Giannitsis, Evangelos , Meex, Steven J.R. , Christenson, Robert H. , Cobbaert, Christa M. , deFilippi, Christopher R. , McCord, James , Omland, Torbjørn , Sandoval, Yader , Tan, Jack Wei Chieh , Than, Martin , Twerenbold, Raphael , Surber, Joseph, Tomaszewski, Christian, Clemency, Brian, Headden, Gary , Cannon, Chad, Knapp, Barry , Tran, Nam K , Niederdöckl, Jan Daniel , Kolev, Emil, Popov, Todor, Sauter, Joachim, Baumann, Sybille , Möeckel, Martin , Müller‐Hennessen, Matthias, Findeisen, Peter, Scharnhorst, Volkher , Omland, T, Krecipro-Nizińska, Ewa, Christ, Michael , Nakagami, Takuo, Huo, Yong

Mayo Clinic

Clinical Chemistry | January 18, 2026 | Volume: 72 | Issue: 4 | Pages: 488-502

10.1093/clinchem/hvag011 | PMID 41564003 Get It

Abstract Background Measurement of cardiac troponin (cTn) using high-sensitivity assays is recommended for the diagnosis of myocardial infarction. We determined sex-specific and uniform 99th percentile upper reference limits (URLs) using the new Elecsys® Troponin T high-sensitivity Gen 6 assay in a global, healthy reference range cohort. Methods Lithium-heparin plasma and serum samples were prospectively collected from apparently healthy individuals aged ≥20 years across 34 global sites in the United States, Europe, China, and Japan. cTnT was measured using the Troponin T high-sensitivity Gen 6 assay on the Cobas® e 801 analyzer. Exclusion criteria were defined according to the 2022 IFCC guidance. Uniform and sex-specific 99th percentile URLs and nonparametric 95% CIs were determined in plasma and serum separately and combined. Results The final study population comprised 4147 participants (52.5% female) with a median (25th–75th percentiles) age of 48.0 (33.0–59.0) years; 45.8%, 47.9%, 5.2%, and 1.1% were White, Asian, Black, and other/unknown, respectively. For sample matrices combined (n = 8294), 81.0% and 99.2% of cTnT values were above the limit of detection in females and males, respectively. Sex-specific 99th percentile URLs (95% CI) were 18 (16–23) ng/L for females and 32 (28–35) ng/L for males; the uniform 99th percentile URL was 27 (24–31) ng/L. URLs were comparable in plasma and serum samples. Conclusions This study determined sex-specific and uniform 99th percentile URLs for the Troponin T high-sensitivity Gen 6 assay that were comparable irrespective of the matrix used in a large, global, healthy reference population.
Cardiac hypertrophy and arrhythmia in mice induced by a mutation in ryanodine receptor 2
Alvarado, Francisco , Yuchi, Zhiguang , Valdivia, Carmen R. , Hernández, Jonathan J. , Zhao, Yan-Ting , Henderlong, Dawn S., Booher, Talia R. , Marcou, Cherisse A. , Petegem, Filip Van , Ackerman, Michael J. , Valdivia, Héctor H. , Bos, J. Martijn , Henderlong, Dawn Shirley, Chen, Yan, Booher, Talia

Mayo Clinic

JCI Insight | March 5, 2019 | Volume: 4 | Issue: 7 | Pages: No page available

10.1172/jci.insight.126544 | PMID 30835254 Get It

Hypertrophic cardiomyopathy (HCM) is triggered mainly by mutations in genes encoding sarcomeric proteins, but a significant proportion of patients lack a genetic diagnosis. We identified a potentially novel mutation in ryanodine receptor 2, RyR2-P1124L, in a patient from a genotype-negative HCM cohort. The aim of this study was to determine whether RyR2-P1124L triggers functional and structural alterations in isolated RyR2 channels and whole hearts. We found that P1124L induces significant conformational changes in the SPRY2 domain of RyR2. Recombinant RyR2-P1124L channels displayed a cytosolic loss-of-function phenotype, which contrasted with a higher sensitivity to luminal [Ca 2+ ], indicating a luminal gain of function. Homozygous mice for RyR2-P1124L showed mild cardiac hypertrophy, similar to the human patient. This phenotype, evident at 1 year of age, was accompanied by an increase in the expression of calmodulin (CaM). P1124L mice also showed higher susceptibility to arrhythmia at 8 months of age, before the onset of hypertrophy. RyR2-P1124L has a distinct cytosolic loss-of-function and a luminal gain-of-function phenotype. This bifunctionally divergent behavior triggers arrhythmias and structural cardiac remodeling, and it involves overexpression of CaM as a potential hypertrophic mediator. This study is relevant to continue elucidating the possible causes of genotype-negative HCM and the role of RyR2 in cardiac hypertrophy.